interferon alfa 2b

Summary

Summary: A recombinant alfa interferon consisting of 165 amino acid residues with arginine in position 23 and histidine in position 34. It is used extensively as an antiviral and antineoplastic agent.

Top Publications

  1. ncbi Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    M P Manns
    Division of Gastroenterology and Hepatology, Medical School of Hannover, Hannover, Germany
    Lancet 358:958-65. 2001
  2. ncbi High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190
    J M Kirkwood
    Department of Pathology, University of Pittsburgh Medical Center, PA 15213 2582, USA
    J Clin Oncol 18:2444-58. 2000
  3. ncbi Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3
    Stefan Zeuzem
    Department of Medicine, Saarland University Hospital, Homburg Saar, Germany
    J Hepatol 40:993-9. 2004
  4. ncbi Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis
    Vincenzo Mazzaferro
    Department of Surgery, Biomedical Statistics, Pathology, National Cancer Institute of Milan and Chair of Gastroenterology, Policlinico Foundation, Department of Medicine, University of Milan, Italy
    Hepatology 44:1543-54. 2006
  5. ncbi Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis
    Bart J Veldt
    Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Ann Intern Med 147:677-84. 2007
  6. ncbi Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    Michael W Fried
    University of North Carolina, Chapel Hill 27599, USA
    N Engl J Med 347:975-82. 2002
  7. ncbi Side effects of therapy of hepatitis C and their management
    Michael W Fried
    Division of Digestive Diseases, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Hepatology 36:S237-44. 2002
  8. ncbi Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C
    John G McHutchison
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Gastroenterology 123:1061-9. 2002
  9. ncbi The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C
    Tarek Hassanein
    Department of Medicine, Division of Gastroenterology and Hepatology, University of California, San Diego, USA
    J Hepatol 40:675-81. 2004
  10. ncbi Biologically active human interferon alpha-2b produced in the egg white of transgenic hens
    Jeffrey C Rapp
    AviGenics, Inc, Georgia BioBusiness Center, 111 Riverbend Rd, Athens, GA 30605, USA
    Transgenic Res 12:569-75. 2003

Detail Information

Publications210 found, 100 shown here

  1. ncbi Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    M P Manns
    Division of Gastroenterology and Hepatology, Medical School of Hannover, Hannover, Germany
    Lancet 358:958-65. 2001
    ..In this randomised trial, peginterferon alfa-2b plus ribavirin was compared with interferon alfa-2b plus ribavirin...
  2. ncbi High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190
    J M Kirkwood
    Department of Pathology, University of Pittsburgh Medical Center, PA 15213 2582, USA
    J Clin Oncol 18:2444-58. 2000
    ..Pivotal trial E1684 of adjuvant high-dose interferon alfa-2b (IFNalpha2b) therapy in high-risk melanoma patients demonstrated a significant relapse-free and overall survival (RFS and OS) benefit compared with observation (Obs)...
  3. ncbi Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3
    Stefan Zeuzem
    Department of Medicine, Saarland University Hospital, Homburg Saar, Germany
    J Hepatol 40:993-9. 2004
    ..The aim of the present study was to investigate this schedule for HCV-2/3 infected patients in the era of pegylated interferon-alpha plus ribavirin...
  4. ncbi Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis
    Vincenzo Mazzaferro
    Department of Surgery, Biomedical Statistics, Pathology, National Cancer Institute of Milan and Chair of Gastroenterology, Policlinico Foundation, Department of Medicine, University of Milan, Italy
    Hepatology 44:1543-54. 2006
    ..3; 95% CI: 0.09-0.9; P = .04). In conclusion, IFN does not affect overall prevention of HCC recurrence after resection, but it may reduce late recurrence in HCV-pure patients receiving effective treatment...
  5. ncbi Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis
    Bart J Veldt
    Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Ann Intern Med 147:677-84. 2007
    ..Clinical outcomes of chronic hepatitis C infection in patients with advanced fibrosis include liver failure, hepatocellular carcinoma, and death...
  6. ncbi Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    Michael W Fried
    University of North Carolina, Chapel Hill 27599, USA
    N Engl J Med 347:975-82. 2002
    ..We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic hepatitis C...
  7. ncbi Side effects of therapy of hepatitis C and their management
    Michael W Fried
    Division of Digestive Diseases, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Hepatology 36:S237-44. 2002
    ..Strategies to maximize adherence are being developed and, in the future, may include early identification of and therapy for depression and the selective use of hematopoietic growth factors to ameliorate hematologic abnormalities...
  8. ncbi Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C
    John G McHutchison
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Gastroenterology 123:1061-9. 2002
    ..We evaluated the impact of adherence to combination therapy with interferon or peginterferon plus ribavirin in chronic hepatitis C patients...
  9. ncbi The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C
    Tarek Hassanein
    Department of Medicine, Division of Gastroenterology and Hepatology, University of California, San Diego, USA
    J Hepatol 40:675-81. 2004
    ..We examined the impact of these treatments on health related quality of life (HRQOL)...
  10. ncbi Biologically active human interferon alpha-2b produced in the egg white of transgenic hens
    Jeffrey C Rapp
    AviGenics, Inc, Georgia BioBusiness Center, 111 Riverbend Rd, Athens, GA 30605, USA
    Transgenic Res 12:569-75. 2003
    ..These results support the potential of the hen as a bioreactor for the production of commercially valuable, biologically active, and glycosylated proteins in egg white...
  11. ncbi Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b
    Zoya R Yurkovetsky
    University of Pittsburgh Cancer Institute, Pennsylvania 15213, USA
    Clin Cancer Res 13:2422-8. 2007
    ..Development of reliable serum assays may contribute to the development of methods for earlier detection of melanoma and the selection of patients who may be most susceptible to current available interventions with IFNalpha...
  12. ncbi Treatment of chronic hepatitis C infection with peginterferons plus ribavirin
    Michael W Fried
    University of North Carolina, Chapel Hill, North Carolina 27599 7080, USA
    Semin Liver Dis 24:47-54. 2004
    ..This article reviews the data from clinical trials of peginterferon alfa-2a and peginterferon alfa-2b...
  13. ncbi Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study
    B F Cole
    Brown University School of Medicine, Providence, RI 02912, USA
    J Clin Oncol 14:2666-73. 1996
    ..To evaluate the quality-of-life effects of adjuvant high-dose interferon alfa-2b (IFN alpha 2b) treatment of high-risk melanoma...
  14. ncbi Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3
    Alessandra Mangia
    Gastroenterology Unit, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
    N Engl J Med 352:2609-17. 2005
    ..We hypothesized that in patients with hepatitis C virus (HCV) genotype 2 or 3 in whom HCV RNA is not detectable after 4 weeks of therapy, 12 weeks of treatment is as effective as 24 weeks...
  15. ncbi Secretory expression of interferon-alpha 2b in recombinant Pichia pastoris using three different secretion signals
    Anand Ghosalkar
    Indian Institute of Technology Delhi, Hauz Khas, New Delhi 110016, India
    Protein Expr Purif 60:103-9. 2008
    ..The difference in the molecular masses of the two bands was found to arise due to the difference in the molecular masses of the N-terminal fragment, and the inefficient processing of secretion signal...
  16. ncbi Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C
    Jens Rasenack
    Klinikum der Albert Ludwigs Universität, Freiburg, Germany
    Pharmacoeconomics 21:341-9. 2003
    ..Treatment with peginterferon alpha-2a (40kD) provides an improved sustained response over unmodified interferon alpha-2a...
  17. ncbi Treatment of chronic hepatitis C: a systematic review
    Geetanjali Chander
    Department of Medicine and Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Hepatology 36:S135-44. 2002
    ..Thus, the combination of peginterferon and ribavirin was the most efficacious treatment in patients with HCV genotype 1. Long-term outcomes were improved in patients with hepatitis C who achieved an SVR with treatment...
  18. ncbi Pegylated interferons: what role will they play in the treatment of chronic hepatitis C?
    M L Shiffman
    Hepatology Section, Medical College of Virginia Commonwealth University, Box 980341, Richmond, VA 23298, USA
    Curr Gastroenterol Rep 3:30-7. 2001
    ..The role PEG-interferons will play in patients who have either relapsed or failed to respond to previous interferon or interferon/ribavirin therapy remains to be defined...
  19. ncbi Recombinant interferon alfa 2b therapy in a patient with metastatic hepatocellular carcinoma
    Man Fung Yuen
    Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong
    J Clin Gastroenterol 35:272-5. 2002
    ..The time for its administration can also serve as an observation period, which is vital in deciding whether definitive surgical treatment of any residual lesions is indicated...
  20. ncbi Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C
    R Perrillo
    Division on Gastroenterology, Ochsner Clinic Foundation, New Orleans, LA 70121, USA
    J Viral Hepat 11:157-65. 2004
    ..Patients randomized to pegIFNalpha 2a had improved work productivity, less activity impairment, decreased need for prescription drugs to treat adverse effects, and better adherence to therapy...
  21. ncbi Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
    Alexander M M Eggermont
    Erasmus University Medical Center, Rotterdam, Netherlands
    Lancet 372:117-26. 2008
    ..Any benefit of adjuvant interferon alfa-2b for melanoma could depend on dose and duration of treatment. Our aim was to determine whether pegylated interferon alfa-2b can facilitate prolonged exposure while maintaining tolerability...
  22. ncbi Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10
    Gamini Soori
    Alegent Bergan Mercy Medical Center, Omaha, NB, USA
    Cancer Biother Radiopharm 17:165-73. 2002
    ..Pilot studies from other investigators have suggested that combining cis-retinoic acid and 5-fluorouracil (5FU) with interleukin-2 (IL-2) and interferon-alpha (IFN) may improve outcomes for such patients...
  23. ncbi The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity
    J G McHutchison
    Scripps Clinic and Research Foundation, La Jolla, CA 92037, USA
    J Hepatol 34:140-7. 2001
    ..Interferon plus ribavirin is the most effective therapy for chronic hepatitis C. The aim of this study was to evaluate the effect of chronic hepatitis C and therapy on health-related quality of life and work functioning...
  24. ncbi High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801
    J M Kirkwood
    Division of Hematology Oncology and Department of Pathology, Department of Medicine, University of Pittsburgh Cancer Institute Melanoma Center, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 2582, USA
    J Clin Oncol 19:2370-80. 2001
    ....
  25. ncbi Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy
    Thomas Berg
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Universitatsklinikum Charite, Campus Virchow Klinikum, Humboldt Universitat, Berlin, Germany
    Hepatology 37:600-9. 2003
    ..This algorithm recognizes 53.7% of nonresponders previously identified at week 24 of treatment...
  26. ncbi Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
    Stefan Zeuzem
    Clinic of Internal Medicine II, Department of Medicine, Saarland University Hospital, Kirrbergerstrasse, 66421 Homburg Saar, Germany
    J Hepatol 44:97-103. 2006
    ..The aim of the present study was to investigate this schedule in the era of pegylated interferon-alpha plus ribavirin...
  27. ncbi Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia
    K Lindahl
    Division of Infectious Diseases, Department of Medicine, Karolinska Institute and Huddinge University Hospital, Stockholm, Sweden
    J Viral Hepat 11:84-7. 2004
    ..This lends further support to the idea that ribavirin should be dosed according to renal function...
  28. ncbi Prognostic significance of autoimmunity during treatment of melanoma with interferon
    Helen Gogas
    First Department of Medicine, Laiko Hospital, Athens, Greece
    N Engl J Med 354:709-18. 2006
    ..We assessed the prognostic significance of autoimmunity in patients with stage IIB, IIC, or III melanoma who were treated with high-dose adjuvant interferon alfa-2b...
  29. ncbi Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy
    John M Kirkwood
    University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    J Clin Oncol 20:3703-18. 2002
    ..It is important to understand the expected adverse events and their underlying mechanisms and to anticipate and aggressively manage toxicity during treatment in order to ensure that patients receive the maximum therapeutic benefit...
  30. ncbi Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C
    Francesc Puig-Basagoiti
    Liver Unit, Institut de Malalties Digestives, Departament de Medicina IMD, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, University of Barcelona, Spain
    J Gen Virol 86:1067-75. 2005
    ..These observations suggest that the composition and dynamics of HCV NS5A quasispecies, particularly in the V3 domain, may play a role in the response to combined IFN/ribavirin therapy...
  31. ncbi Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK/STAT pathway
    Michael J Grace
    Schering Plough Research Institute, Biotechnology Development, Union, NJ, USA
    Antivir Chem Chemother 15:287-97. 2004
    ..The elucidation of the in vitro effects of pegylation is important and this will ultimately have a positive impact on the in vivo efficacy of treatment for patients with hepatitis C...
  32. ncbi Chronic hepatitis C. Genotypes and response to anti-viral therapy among Saudi patients
    Ibrahim Al-Traif
    Department of Hepatobiliary Sciences and Liver Transplant 1440, King Abdul Aziz Medical City, King Fahad National Guard Hospital, PO Box 22490, Riyadh 11426, Kingdom of Saudi Arabia
    Saudi Med J 25:1935-8. 2004
    ..The aim of this study is to compare the response of hepatitis C virus (HCV) genotype 4 with other genotypes to anti-viral treatment among Saudi patients in a prospective randomized trial...
  33. ncbi Pegylated interferon and ribavirin-induced interstitial pneumonitis with ARDS
    Sandra Abi-Nassif
    Department of Pharmacy, Division of Pulmonary and Critical Care, and Massachusetts General Hospital, Boston, MA 02114, USA
    Chest 124:406-10. 2003
    ..He developed ARDS and died after 26 days of hospitalization from multisystem organ failure. This case suggests that interstitial pulmonary disease can occur with pegylated interferon-alpha(2)b therapy...
  34. ncbi Side effects of therapy for chronic hepatitis C
    Mark W Russo
    Division of Digestive Diseases, University of North Carolina at Chapel Hill, 27599, USA
    Gastroenterology 124:1711-9. 2003
  35. ncbi Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses
    Stergios J Moschos
    Melanoma and Skin Cancer Program, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Clin Oncol 24:3164-71. 2006
    ..Therefore, HDI was investigated in the neoadjuvant setting to assess clinical and pathologic responses after 4 weeks of HDI and to perform immunohistochemical evaluation of immune cell subsets and melanoma-associated antigens...
  36. ncbi Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C
    Xuhuai Ji
    Department of Medicine, Stanford University School of Medicine, Stanford, Palo Alto, CA 94304, USA
    Hepatology 37:610-21. 2003
    ..In conclusion, IFN-alpha-inducible genes can be identified in human PBMCs in vivo as well as ex vivo. Signature changes associated with different treatment outcomes may be found among these genes...
  37. ncbi Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy
    Stephen B Tucker
    Department of Dermatology, The University of Texas Medical School at Houston, Texas, USA
    J Am Acad Dermatol 54:1033-8. 2006
    ..Interferon alfa-2b (IFN) may be used to treat basal cell carcinoma (BCC) as an alternative to surgical or destructive methods...
  38. ncbi Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, Paris, France
    Gastroenterology 122:1303-13. 2002
    ..Liver fibrosis is an important prognostic factor in patients with hepatitis C. The effect of pegylated (PEG) interferon alone or its combination with ribavirin on fibrosis has not been established...
  39. ncbi The increasing problem of hepatitis C virus infection
    E A Coates
    South Australian Dental Service, Adelaide Dental Hospital
    Aust Dent J 46:13-7; quiz 53. 2001
    ..This paper discusses the issues associated with treating patients who have HCV infection including the importance of preventive programs to reduce dental pathology and maximise oral health...
  40. ncbi Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)
    T Poynard
    Groupe Hospitalier, Faculté Pitie Salpêtrière, Universite Paris VI, URA CNRS 1484, France
    Lancet 352:1426-32. 1998
    ..The aim of this study was to compare the efficacy and safety of interferon alpha2b in combination with oral ribavirin with interferon alone, for treatment of chronic infection with hepatitis C virus (HCV)...
  41. ncbi Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C
    K R Reddy
    University of Miami School of Medicine, Miami, FL, USA
    Hepatology 33:433-8. 2001
    ..The 180-microg PEG(40kd) IFN alpha-2a dose appeared to be the optimal dose based on sustained virological response and its associated side-effect profile...
  42. ncbi Effects of high-dose IFNalpha2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3, and IL-17
    Wenjun Wang
    Department of Medicine, Division of Hematology Oncology, Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213 2584, USA
    Clin Cancer Res 14:8314-20. 2008
    ..The effects of IFNalpha on STAT signaling in relation to tumor tissue Treg and Th17 have not been documented in humans beyond the observations that IFNalpha2b down-regulates STAT3...
  43. ncbi Predictors of response of US veterans to treatment for the hepatitis C virus
    Lisa I Backus
    Center for Quality Management in Public Health, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA
    Hepatology 46:37-47. 2007
    ..For genotype 3 patients, only receiving PEG-INF 2A affected the likelihood of an SVR; its effect was positive...
  44. ncbi Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Hepatology 46:371-9. 2007
    ..SVR was significantly greater (P < 0.05) in group 3 patients (49%). This resulted from a significant decline (P < 0.05) in relapse rate; only 8% versus 38% for groups 1 and 2...
  45. ncbi Transgenic avian-derived recombinant human interferon-alpha2b (AVI-005) in healthy subjects: an open-label, single-dose, controlled study
    T B Patel
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Int J Clin Pharmacol Ther 45:161-8. 2007
    ..This study characterized the safety and pharmacological properties of AVI-005, a novel glycosylated recombinant human interferon-alpha2b produced from the egg whites of chickens transfected with human cDNA...
  46. ncbi Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy
    John G McHutchison
    Duke Clinical Research Institute, Division of Gastroenterology Duke University, Durham, North Carolina 27705, USA
    Am J Gastroenterol 102:880-9. 2007
    ..In the meantime, physicians must make the best possible use of the available options for managing anemia, especially in select patient groups who are most at risk for anemia and its complications...
  47. ncbi A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C
    K L Lindsay
    University of Southern California, Los Angeles, CA 90033, USA
    Hepatology 34:395-403. 2001
    ..The higher rate of virologic response during treatment with 1.5 microg/kg peginterferon alfa-2b in patients infected with genotype 1 and high viral levels warrants further evaluation...
  48. ncbi Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial
    G H Mickisch
    Erasmus University and Academic Hospital Rotterdam Dijkzigt, Rotterdam, Netherlands
    Lancet 358:966-70. 2001
    ..We aimed to establish whether radical nephrectomy done before interferon-alfa-based immunotherapy improved time to progression and overall survival (primary endpoints) compared with interferon alfa alone...
  49. ncbi Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer
    Y Z Patt
    Department of Gastrointestinal Medical Oncology and Digestive Diseases, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 7:3375-80. 2001
    ..Therefore, this regimen cannot be recommended for cholangiocarcinoma, but it may have a role in the treatment of gallbladder carcinoma, particularly among patients who were refractory to higher priority investigational agents...
  50. ncbi Pegylated interferon alfa 2b and oral ribavirin in patients with HCV-related cirrhosis
    Ajit Sood
    Dayanand Medical College and Hospital, Ludhiana, Punjab, India
    Indian J Gastroenterol 25:283-5. 2006
    ..We retrospectively reviewed the case records of patients with HCV cirrhosis to evaluate the efficacy and tolerability of pegylated (peg) interferon and ribavirin treatment in these patients...
  51. ncbi Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b
    S A Rosenberg
    Surgery Branch and Department of Biostatistics and Data Management Section, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Clin Oncol 17:968-75. 1999
    ..We have performed a prospective randomized trial in patients with metastatic melanoma, comparing treatment with chemotherapy to treatment with chemoimmunotherapy...
  52. ncbi Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy
    Gregory B Lesinski
    Department of Human Cancer Genetics, Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA
    J Natl Cancer Inst 96:1331-42. 2004
    ..We used a novel flow cytometric assay to examine phosphorylation-mediated activation of STAT1 within immune effector cell subsets following in vitro or in vivo IFN alpha treatments...
  53. ncbi A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma
    John M Kirkwood
    University of Pittsburgh Medical Center, Department of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Clin Cancer Res 10:1670-7. 2004
    ..The objectives of this study were to update the analyses of each individual trial and to analyze prognostic factors and treatment effects based on pooled data...
  54. ncbi Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial
    Alessandra Mangia
    Gastroenterology, Istituto di Ricovero e Cura a Carattere Scientifico, Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
    Hepatology 47:43-50. 2008
    ..RVR patients with baseline viremia >or=400,000 IU/mL achieved higher SVR rates when treated for 48 weeks rather than 24 weeks (86.8% versus 73.1%, P = 0.14). The only predictive factor of SVR in RVR patients was advanced fibrosis...
  55. ncbi Ribavirin, but not interferon alpha-2b, is associated with impaired osteoblast proliferation and differentiation in vitro
    R O Moreira
    Division of Endocrinology, Hospital Universitario Clementino Fraga Filho HUCFF, Rio de Janeiro, Brazil
    Calcif Tissue Int 75:160-8. 2004
    ..These negative effects of ribavirin on osteblast-like cells might contribute to the bone loss reported in vivo...
  56. ncbi Adherence to hepatitis C treatment in recovering heroin users maintained on methadone
    Diana L Sylvestre
    Department of Medicine, University of California, San Francisco, Oakland, California 94612, USA
    Eur J Gastroenterol Hepatol 19:741-7. 2007
    ..We sought to define the impact of these and other potential adherence barriers in a real-world sample of recovering drug users...
  57. ncbi Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
    Gary L Davis
    Division of Hepatology, Baylor University Medical Center, Dallas, TX 75246, USA
    Hepatology 38:645-52. 2003
    ..Patients who fail to achieve EVR will not clear virus even if an additional 9 months of therapy is received. Therapy can be confidently discontinued in those cases...
  58. ncbi Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b
    Wenjun Wang
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh, Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute Pittsburgh, PA, USA
    Clin Cancer Res 13:1523-31. 2007
    ..The goal of this study was to understand the effects of high-dose IFNalpha2b (HDI) in relation to the balance of pSTAT1 and pSTAT3...
  59. ncbi Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study
    Olav Dalgard
    Department of Medicine, Aker University Hospital, Oslo, Norway
    Hepatology 40:1260-5. 2004
    ..The results need to be confirmed in a randomized, controlled study before this treatment approach can be recommended, particularly for patients with genotype 3 and high viral load or severe fibrosis...
  60. ncbi Peginterferon and ribavirin for chronic hepatitis C
    Jay H Hoofnagle
    Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA
    N Engl J Med 355:2444-51. 2006
  61. ncbi Where are we with adjuvant therapy of stage III and IV melanoma in 2009?
    Leslie A Fecher
    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
    J Natl Compr Canc Netw 7:295-304. 2009
    ..This article explores the factors to consider when individualizing care within the scope of these guidelines...
  62. ncbi Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
    R C Flanigan
    Loyola University Stritch School of Medicine, Maywood, Ill, USA
    N Engl J Med 345:1655-9. 2001
    ..The value of nephrectomy in metastatic renal-cell cancer has long been debated. Several nonrandomized studies suggest a higher rate of response to systemic therapy and longer survival in patients who have undergone nephrectomy...
  63. pmc Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy
    Milton W Taylor
    Department of Biology, Indiana University, Bloomington, IN 47401, USA
    J Virol 81:3391-401. 2007
    ..No specific regulatory gene could be identified as responsible for this global blunting or the racial differences...
  64. ncbi Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma
    E Bajetta
    Medical Oncology Unit 2, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Ann Oncol 17:571-7. 2006
    ..In this phase III trial, we compared the effects of CT [cisplatin, vindesine and dacarbazine (CVD)] with those of concurrent biochemotherapy (bioCT) consisting of CVD plus interleukin-2 and interferon-alpha2b...
  65. ncbi Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b
    Michael D Boehm
    Department of Ophthalmology, University of Minnesota, Minneapolis 55455, USA
    Ophthalmology 111:1755-61. 2004
    To evaluate topical interferon alfa 2b (IFNalpha2b) as a single therapeutic agent in the treatment of presumed recurrent corneal and conjunctival intraepithelial neoplasia.
  66. ncbi Hepatitis C treatment update
    Brian L Pearlman
    Center For Hepatitis C, Atlanta Medical Center, Atlanta, Georgia 30312, USA
    Am J Med 117:344-52. 2004
    ..Four broad groups of investigational therapeutic agents appear promising for future therapy: modified interferons and ribavirins, immunomodulators, viral life-cycle targets, and antifibrotic agents...
  67. ncbi Regulation of gene expression by pegylated IFN-alpha2b and IFN-alpha2b in human peripheral blood mononuclear cells
    Diana L Brassard
    Department of Biotechnology, Schering Plough Research Institute, Union, NJ 07083, USA
    J Interferon Cytokine Res 24:455-69. 2004
    ....
  68. ncbi Side effects of medical therapy for chronic hepatitis C
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, 23298, USA
    Ann Hepatol 3:5-10. 2004
    ..Appropriate recognition and management of these side effects will both improve response to therapy and avoid unnecessary morbidity and mortality...
  69. ncbi Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma
    Dimitrios Pectasides
    Second Department of Internal Medicine Propaedeutic, Oncology Section, University General Hospital Attikon, Athens, Greece
    J Clin Oncol 27:939-44. 2009
    ....
  70. ncbi Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy
    Thierry Poynard
    Service d Hepatologie, Université Pierre et Marie Curie Liver Center, hôpital La Pitié Salpêtrière, Paris, France
    Gastroenterology 136:1618-28.e2. 2009
    ..Alternate options are needed for patients who relapse or do not respond to therapy...
  71. ncbi Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway
    Michael J Grace
    Schering Plough Research Institute, Biotechnology Development, Bioanalytical and Process Development, Union, New Jersey 07083 and Aventis Pharmaceuticals, Medical Affairs Oncology, Bridgewater, New Jersey 08807, USA
    J Biol Chem 280:6327-36. 2005
    ..The higher specific activity associated with the His(34) positional isomer suggests that this site may be favorable for pegylating IFN-alpha2b molecules...
  72. ncbi Severe interstitial pneumonitis secondary to pegylated interferon alpha-2b and ribavirin treatment of hepatitis C infection
    Valentin Fuhrmann
    Department of Internal Medicine 4, General Hospital and University of Vienna, Vienna, Austria
    Dig Dis Sci 49:1966-70. 2004
  73. ncbi Incidence and risk factors for weight loss during dual HIV/hepatitis C virus therapy
    Vincent Lo Re
    Division of Infectious Diseases, Department of Medicine, University of Pennsylvania School of Medicine, 423 Guardian Drive, Philadelphia, PA 19104, USA
    J Acquir Immune Defic Syndr 44:344-50. 2007
    ..Clinical observations suggest that patients with HIV/hepatitis C virus (HCV) may lose body weight during dual therapy, but this has not been confirmed analytically...
  74. ncbi Weight-based combination therapy with peginterferon alpha-2b and ribavirin for naïve, relapser and non-responder patients with chronic hepatitis C
    Fernando Lopes Gonçales Jr
    Faculty of Medical Sciences of Campinas, Campinas, SP, Brazil
    Braz J Infect Dis 10:311-6. 2006
    ..All of the non-responder patients who did not have EVR reached SVR. Treatment was discontinued in 13% of the patients, due to loss to follow-up, hematological abnormalities or depression...
  75. ncbi Sustained viral response to pegylated interferon alpha-2b and ribavirin in chronic hepatitis C refractory to prior treatment
    A Mathew
    Division of Gastroenterology and Hepatology, Department of Medicine, Pan State Milton S Hershey Medical Center, Pennsylvania State University, P O Box 850, H045, Hershey, Pennsylvania 17033 0850, USA
    Dig Dis Sci 51:1956-61. 2006
    ..The most important factor in predicting response to therapy is the manner of response to previous treatment. The likelihood of response to treatment can be predicted from the viral titers at 24 weeks...
  76. ncbi Efficacy, tolerability and predictive factors for early and sustained virologic response in patients treated with weight-based dosing regimen of PegIFN alpha-2b ribavirin in real-life healthcare setting
    Liana Gheorghe
    Department of Hepatology, Center of Gastroenterology and Hepatology, Fundeni Clinical Institute, Str Fundeni no 258, 72437 Bucharest, Romania
    J Gastrointestin Liver Dis 16:23-9. 2007
    ....
  77. ncbi Efficient expression and purification of human interferon alpha2b in the methylotrophic yeast, Pichia pastoris
    Linmei Shi
    School of Environmental Engineering, Lishui Vocational and Technical College, Lishui, Zhejiang, PR China
    Protein Expr Purif 54:220-6. 2007
    ..9 x 10(9)IU/mg. Our results suggest that the P. pastoris expression system can be used to produce large quantities of fully functional hIFN-alpha2b for both research and industrial purpose...
  78. ncbi Therapy of hepatitis C: from empiricism to eradication
    Jean Michel Pawlotsky
    Hopital Henri Mondor, Creteil, France
    Hepatology 43:S207-20. 2006
    ..New treatments and vaccines might make it possible to eradicate HCV in the future...
  79. ncbi Assessment of early virological response to antiviral therapy by comparing four assays for HCV RNA quantitation using the international unit standard: implications for clinical management of patients with chronic hepatitis C virus infection
    Philippe Halfon
    Alphabio Laboratory, Marseille, France
    J Med Virol 78:208-15. 2006
    ..All assays, however, failed to detect HCV RNA in some cases. Despite the use of the IU standard HCV-infected patients might be monitored with only one assay...
  80. ncbi Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C
    Edward L Krawitt
    Department of Medicine, University of Vermont, Burlington, VT, USA
    J Hepatol 43:243-9. 2005
    ..However, little is known about the utility of such regimens for individuals who failed to respond to prior conventional interferon-based treatment...
  81. ncbi Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection
    Alessio Aghemo
    A M Migliavacca Centre for Liver Disease, Division of Gastroenterology, Fondazione IRCCS Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Antivir Ther 11:797-802. 2006
    ..Evaluation of liver fibrosis is important in the management of patients with genotype 3a hepatitis C, since it helps to predict response to IFN/RBV therapy...
  82. ncbi Interstitial pneumonia recurrence during chronic hepatitis C treatment
    Christophe Renou
    Am J Gastroenterol 100:1625-6. 2005
  83. ncbi Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection
    Abdurrahman Sagir
    Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Universitätsklinik Düsseldorf, Dusseldorf, Germany
    Liver Int 27:954-9. 2007
    ..In this report, we investigated response rates to combination therapy [standard IFN-alpha or PEG-IFN-alpha and ribavirin] in patients who relapsed or failed in prior therapy...
  84. ncbi Overexpression and purification of recombinant human interferon alpha2b in Escherichia coli
    Poonam Srivastava
    Centre for Biotechnology, Jawaharlal Nehru University, New Delhi 110067, India
    Protein Expr Purif 41:313-22. 2005
    ..The bioassay of the refolded protein gave a specific activity of approximately 3 x 10(9)IU/mg protein...
  85. ncbi Interferon and ribavirin with or without amantadine for interferon non-responders with chronic hepatitis C. A randomized, controlled pilot study
    Christa Wenger
    Gastroenterology and Hepatology, University Hospital Zurich, Switzerland
    Swiss Med Wkly 137:418-23. 2007
    ..Our aim was to compare efficacy and tolerability of an interferon-alfa-2a (INF), ribavirin (RIBA) and amantadine (AMA) combination with those of an INF and RIBA combination...
  86. ncbi Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response
    Olav Dalgard
    Infectious Disease Department, Ulleval University Hospital, Oslo, Norway
    Hepatology 47:35-42. 2008
    ..7-17.7). Among patients with an HCV RNA test 24 weeks after the end of treatment, 120 of 139 (86.3%) patients in group A achieved SVR compared with 136 of 146 (93.2%) in group B (difference, 6.9%; 95% confidence interval, -0.1 to +13.9)...
  87. ncbi High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy
    Rami Moucari
    Service d hépatologie and INSERM CRB3, Hopital Beaujon, AP HP, Universite Paris VII, Clichy, France
    J Hepatol 46:596-604. 2007
    ..To evaluate the efficacy of peginterferon alfa-2b and ribavirin in unselected consecutive patients with chronic hepatitis C, treated outside of trials, who were relapsers or non-responders to interferon and ribavirin combination...
  88. ncbi Guidelines for stopping therapy in chronic hepatitis C
    Mark W Russo
    Division of Gastroenterology and Hepatology, University of North Carolina, CB 7080, Room 1111, Bioinformatics Building, Mason Farm Road, Chapel Hill, NC 27599, USA
    Curr Gastroenterol Rep 6:17-21. 2004
    ..Progress in defining early treatment stopping points has reduced adverse events in patients who are unlikely to respond to therapy...
  89. ncbi Purification and conformational properties of a human interferon alpha2b produced in Escherichia coli
    A Beldarrain
    Processes and Systems Evaluation Department, Production Plant, CIGB Center for Genetic Engineering and Biotechnology, P O Box 6162, Havana, Cuba
    Biotechnol Appl Biochem 33:173-82. 2001
    ..0, the most stable condition, the conformational stability depends on protein concentration and ionic strength. The highly helical secondary structure is very conserved over the whole pH range studied, including at high temperatures...
  90. ncbi Treatment of acute hepatitis C virus infection
    W Vogel
    Department of Gastroenterology and Hepatology, Innsbruck University
    J Hepatol 31:189-92. 1999
    ..More studies are needed to define the role of a higher dose and the start of treatment...
  91. ncbi The role of interferon alpha 2b as an adjunctive treatment in the management of aggressive basal cell carcinoma of the eyelids
    S Fenton
    Acta Ophthalmol Scand 80:674-5. 2002
  92. ncbi Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group
    J E Ware
    Health Assessment Lab, New England Medical Center, Boston, MA, USA
    Hepatology 30:550-5. 1999
    ..Successful treatment of CHC improved HQL as measured by both CHC-specific and generic measures of functional health and well being...
  93. ncbi [Induced interstitial pneumonitis: role of pegylated interferon alpha 2b]
    Pierre Rocca
    Fédération des spécialités digestives, Hopital Edouard Herriot, France
    Gastroenterol Clin Biol 26:405-8. 2002
    ..We discuss the causes of these rare pulmonary alpha-interferon induced complications and the different way to suggest that the pegylated interferon alpha 2b could be related to the risk of pulmonary toxicity of this treatment...
  94. ncbi Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study
    Sanjiv S Agarwala
    Melanoma Center, Cancer Institute, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    Cancer 97:121-7. 2003
    ....
  95. ncbi Biologic activity of polyethylene glycol12000-interferon-alpha2b compared with interferon-alpha2b: gene modulatory and antigrowth effects in tumor cells
    Keyur Vyas
    Cleveland Clinic Taussig Cancer Center and Lerner Research Institute, Ohio, USA
    J Immunother 26:202-11. 2003
    ..Therefore, although the specific activity of IFN-alpha2b is approximately three times greater than PEG-IFN-alpha2b, the two preparations have identical in vitro biologic activities when applied to cells at equivalent antiviral units...
  96. ncbi Secretion of human interferon alpha 2b by Streptomyces lividans
    E Pimienta
    Departamento de Biotecnologia, Centro de Química Farmacéutica, Ciudad de La Habana, Cuba
    Appl Microbiol Biotechnol 58:189-94. 2002
    ..Experimental evidence suggests that the degrading factor is related to mycelium-associated proteolytic activity...
  97. ncbi Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin
    John G McHutchison
    Division of Gastroenterology Hepatology, Scripps Clinic and Research Foundation, 10666 N Torrey Pines Road N203, La Jolla, CA 92037, USA
    Hepatology 35:688-93. 2002
    ..In conclusion, measurement of hepatic HCV RNA before or after therapy reflects changes observed in serum HCV RNA, and correlates inversely with hepatic inflammation and fibrosis, but otherwise has minimal clinical use...
  98. ncbi Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University, Richmond, 23298, USA
    Gastroenterology 126:1015-23; discussion 947. 2004
    ..This study evaluated the effectiveness of this treatment in patients who were nonresponders to previous interferon-based therapy...
  99. ncbi Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b
    Gaetano Scotto
    Clinic of Infectious Diseases, University of Foggia, Foggia, Italy
    Drugs 68:791-801. 2008
    ....
  100. ncbi Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study
    Amparo Escudero
    Service of Hepatology, University Hospital Clinic, Department of Medicine, University of Valencia, Valencia, Spain
    J Gastroenterol Hepatol 23:861-6. 2008
    ....
  101. ncbi Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3
    Thomas Berg
    Charite Universitatsmedizin Berlin, Berlin, Germany
    Antivir Ther 13:17-22. 2008
    ..As in genotype 1 and 4 patients, response-guided therapy aims to optimize treatment outcomes for individuals, without compromising SVR rates...

Research Grants41

  1. GANGLIOSIDE GD2 AS TARGET FOR IMMUNOTHERAPY IN MELANOMA
    Kenneth Foon; Fiscal Year: 2004
    ..The third objective is correlation of the quantitative IgG anti-GD2 response with relapse free and overall survival. The fourth is to monitor toxicity. ..
  2. Differential cytokine responses in Hep C patients.
    Milton Taylor; Fiscal Year: 2005
    ..We will attempt to establish an in vitro system that mimics in vivo events. This combination of experiments should identify factors that are important in the differential responses to treatment and viral resistance. ..
  3. Cellular Immune Responses in Subjects Exposed to Hepatitis C
    Sanaa Kamal; Fiscal Year: 2008
    ..Our long-term goal is to mimic this response to develop vaccine strategies or therapeutic protocols capable of preventing persistent hepatitis C infection. [unreadable] [unreadable] [unreadable]..
  4. Signaling Pathways in Hepatic Fibrogenesis
    Bruce Bacon; Fiscal Year: 2005
    ..Since activated HSC play a key role in hepatic fibrogenesis, these experiments will contribute to an improved understanding of the basic biochemical processes underlying hepatic fibrosis. ..
  5. Features of HCV and Schistosoma mansoni coinfection
    Sanaa Kamal; Fiscal Year: 2004
    ..It is anticipated that investigating this pattern of viral-parasitic interaction will projects will provide useful information for development of more effective diagnostic, prevention and treatment strategies. ..
  6. HEPATITIS C VIRAL QUASISPECIES WITHIN THE LIVER
    Adrian Di Bisceglie; Fiscal Year: 2003
    ..These studies have great potential significance for understanding of viral clearance, development of persistent infection and for the development of a vaccine against HCV. ..
  7. Phase I Clinical Trials of Anti-Cancer Agents
    Francis Giles; Fiscal Year: 2007
    ..abstract_text> ..
  8. Phase II trial of 17-AAG in melanoma patients
    Paul Chapman; Fiscal Year: 2007
    ..post-treatment specimens, clinically responding tumors vs. non-responding tumors, and mutant BRAF vs. wild-type BRAF tumors. [unreadable] [unreadable] [unreadable]..
  9. Neoadjuvant Cytokine Immunotherapy by PLA Microspheres
    Michael Sabel; Fiscal Year: 2007
    ..I will pursue this area of investigation as a full-time faculty member, with full commitment from the Department of General Surgery and the Division of Surgical Oncology at the University of Michigan Medical Center. ..
  10. Anti-GD3 NKT cells as effector cells against melanoma
    Paul Chapman; Fiscal Year: 2006
    ..This will provide initial support for an immunotherapeutic approach based on antigen-specific NKT cells. [unreadable] [unreadable]..
  11. Mechanisms of Innate and Adaptive Immunity In HCV
    David Nelson; Fiscal Year: 2009
    ..A better understanding of the immunologic factors that determine resolution or persistence of the infection may help in the design of therapies and vaccines for the control of HCV infection. ..
  12. IMMUNIZATION AGAINST TUMOR CELL ANTIGENS
    Paul Chapman; Fiscal Year: 2003
    ..This close mentoring relationship reflects our current teaching paradigm. The grant award will provide the PI with more time to conduct the clinical trials and to mentor additional beginning clinical investigators. ..
  13. CELLULAR IMMUNE RESPONSE IN CHRONIC HEPATITIS C
    David Nelson; Fiscal Year: 2003
    ..These studies will provide insight into basic immunologic principles associated with the host's immune response to this viral infection, as well as provide the basis for new interventional strategies. ..
  14. E2F-1 Cancer Gene Therapy
    Kelly McMasters; Fiscal Year: 2005
    ..These studies will enhance our understanding of E2F-1-mediated cell death and facilitate the design of improved treatment strategies...
  15. Biologic therapy of Melanoma and Renal Cell Cancer
    Michael Atkins; Fiscal Year: 2006
    ..abstract_text> ..
  16. T Lymphocyte Apoptosis in Hepatitis C Persistence
    Margaret Koziel; Fiscal Year: 2006
    ..abstract_text> ..
  17. Apoptosis in myelofibrosis with myeloid metaplasia
    Ruben Mesa; Fiscal Year: 2006
    ..abstract_text> ..
  18. RB4 Intravesical Gene Therapy: Mechanisms of Cell Death
    William Benedict; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  19. Dendrimer aminosaccharide drug to modulate inflammatory responses in shigellosis
    Sunil Shaunak; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  20. Growth Hormone and Rosiglitazone for Visceral Adoposity
    Marshall Glesby; Fiscal Year: 2007
    ..If the results are as predicted, then combination therapy with rhGH and rosiglitazone may prove to be a highly effective treatment for visceral adiposity in HIV-infected patients. ..
  21. Pathophysiology and Characterisation of NAFLD
    Michael Charlton; Fiscal Year: 2009
    ..We believe that these experiments will generate mechanistic insight into the cause and effects of increased oxidative stress in patients with histologically progressive NAFLD. ..
  22. Antiretroviral Therapy and the Hepatitis C Virus
    Kenneth E Sherman; Fiscal Year: 2010
    ....
  23. HIV-Hepatitis C Virus Interactions and Pathogenesis
    Raymond T Chung; Fiscal Year: 2010
    ..These studies will shed considerable light on HIV-HCV pathogenic interactions and offer a means of productively disrupting these interactions. ..
  24. Natural Killer T Cells in an animal model of hepatitis C
    Margaret Koziel; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  25. Interferon-gamma To Treat Chronic HCV Infection
    Andrew Muir; Fiscal Year: 2002
    ..Secondary endpoints include the biochemical response, inflammatory and regulatory cytokine levels, and quality of life during treatment. ..
  26. NOVEL ANIMAL MODELS OF HCV-RELATED HEPATOCARCINOGENESIS
    Raymond Chung; Fiscal Year: 2003
    ..Together, these models will help provide insights into the factors responsible for this devastating complication of chronic HCV infection. ..
  27. OCULAR MELANOMA
    Paul Finger; Fiscal Year: 2003
    ..Standardized clinical and data collection procedures will be employed, and standardized forms will be used in all centers. Central training and certification of all study staff will be required. ..
  28. IMMUNOISOLATION BIOCAPSULES FOR PANCREATIC ISLET CELLS
    Frank Martin; Fiscal Year: 2003
    ..The implant will keep transplanted islet cells sequestered from the recipient's immune system. It will be durable, rechargeable and, if problems develop, removable. ..
  29. VIRAL AND IMMUNE RESPONSE TO THERAPY FOR HIV IN THE GALT
    Andrew Talal; Fiscal Year: 2003
    ..This project amy provide important insights into the amount of time needed to treat HIV- infected individuals and may provide novel approaches by which to monitor therapeutic responses in these individuals. ..
  30. HCV Genomic Variability in HIV Infected Hemophiliacs
    Kenneth Sherman; Fiscal Year: 2004
    ..Treatment nonresponders will be followed in a prospective cohort study for up to 3 additional years so that the evolution of the virus, and its associated immune response in this group can be evaluated. ..
  31. PEPTIDE VACCINES WITH/WITHOUT GMCSF IN STAGE IV MELANOMA
    John Kirkwood; Fiscal Year: 2004
    ..Knowledge of the immune responses to be analyzed here will accelerate progress in the development of vaccines for melanoma on other solid tumors. ..
  32. Suppression of Hepatoma Cell Growth by Celecoxib
    Ke Qin Hu; Fiscal Year: 2004
    ..abstract_text> ..
  33. HCV VARIANTS AND IMMUNE RESPONSE IN INJECTION DRUG USERS
    Teresa Wright; Fiscal Year: 2004
    ..Finally, with the establishment of this cohort, we will be able to store serum and lymphocytes for future analysis of genetic determinants of viral persistence/clearance. ..
  34. Proteomics and Biomarkers for Hepatocellular Cancer
    Nezam Afdhal; Fiscal Year: 2004
    ..cohort of patients with HCV and cirrhosis who are randomized to treatment with either low dose PEGylated interferon alfa 2b or colchicine and are followed for 4 years with rigorous clinical screening for HCC...
  35. Chemical Genetics:Cellular Regulators of HCV (RMI)
    Raymond Chung; Fiscal Year: 2004
    ..Second, discovery of hit compounds that positively or negatively regulate HCV replication will ultimately help lead to identification of novel cellular targets that can be exploited to further interrupt the viral lifecycle. ..
  36. Antiviral Therapy in African Americans with HCV
    Nezam Afdhal; Fiscal Year: 2005
    ..Specimens of liver tissue and serum will be collected for basic studies on viral resistance. These studies should help determine the best therapy for AA with HCV. ..
  37. ESTROGEN, DIET, GENETICS AND ENDOMETRIAL CANCER
    Sara Olson; Fiscal Year: 2005
    ..This study will provide data on genetic susceptibility in endometrial cancer in conjunction with established risk factors, as well as the first epidemiologic data on the more lethal serous and clear cell tumors. ..
  38. PROTEIN LIPID INTERACTIONS IN GALLSTONE PATHOGENESIS
    Nezam Afdhal; Fiscal Year: 2002
    ..These studies may lead to strategies for the prevention and non-surgical therapy of this very common disease. ..
  39. Addiction Medicine Physicians and Care for Hepatitis C
    ALAIN LITWIN; Fiscal Year: 2003
    ..Data from this study will have relevance to both drug abuse treatment policy and clinical practice. ..
  40. Pharmacogenetics of lipid response to estrogen therapy
    Jeanette McCarthy; Fiscal Year: 2009
    ..This may result in future clinically useful diagnostic tests that aid postmenopausal women in their decision whether to use estrogen therapy. ..